Royal Bank Of Canada Initiates Coverage on Biogen Inc. (NASDAQ:BIIB)

Marco Green
September 25, 2017

It has underperformed by 11.76% the S&P500.

Fortaleza Asset Management Inc increased its stake in Biogen Inc. The stock of WisdomTree Investments, Inc. Monsanto Co now has $52.62 billion valuation. The stock decreased 0.58% or $0.11 on September 22, reaching $18.71. Goldman Sachs Grp holds 0.12% of its portfolio in Biogen Inc (NASDAQ:BIIB) for 1.73M shares.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, July 25th. It has underperformed by 7.03% the S&P500.

SunTrust Banks also issued estimates for Biogen's Q3 2017 earnings at $5.79 EPS, Q4 2017 earnings at $5.75 EPS, FY2017 earnings at $21.78 EPS, Q1 2018 earnings at $5.70 EPS, Q2 2018 earnings at $5.95 EPS, Q3 2018 earnings at $6.11 EPS, Q4 2018 earnings at $6.24 EPS, FY2018 earnings at $24.00 EPS, FY2019 earnings at $26.00 EPS, FY2020 earnings at $28.30 EPS and FY2021 earnings at $30.00 EPS. Guardian Life Insurance Co. of America raised its holdings in Biogen by 0.7% in the 1st quarter. It increased, as 38 investors sold HD shares while 632 reduced holdings. TIER's SI was 702,100 shares in September as released by FINRA. Cambridge Research Advsrs Incorporated holds 5,428 shares. (NASDAQ:BIIB) by 50.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. Winfield holds 151 shares. New Amsterdam Prtnrs Limited Company holds 1,471 shares or 0.08% of its portfolio. Thompson Rubinstein Investment Management Or reported 3.34% stake. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company's stock worth $123,000 after purchasing an additional 219 shares during the last quarter. Private Trust Na has invested 0.05% in Biogen Inc (NASDAQ:BIIB). Regions Financial Corp holds 0.02% or 5,051 shares in its portfolio. Corporate insiders own 0.32% of the company's stock. Moreover, Gabelli Funds Limited has 0.15% invested in Monsanto Company (NYSE:MON). Bradley Foster & Sargent Ct, Connecticut-based fund reported 4,423 shares. GRANT HUGH also sold $17.33M worth of Monsanto Company (NYSE:MON) shares. Shares for $14.21 million were sold by Menear Craig A. 25,000 Monsanto Company (NYSE:MON) shares with value of $2.94 million were sold by BEGEMANN BRETT D. Shares for $1.33M were sold by Preete Kerry J. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company's stock valued at $229,000 after buying an additional 6 shares during the last quarter. Therefore 55% are positive. The stock has "Buy" rating by Nomura on Friday, July 14. On Thursday, August 27 the stock rating was reinitiated by Morgan Stanley with "Overweight". The firm has "Top Pick" rating given on Friday, October 28 by RBC Capital Markets. The rating was maintained by Jefferies with "Hold" on Wednesday, August 30. BMO Capital Markets boosted their target price on Biogen from $328.00 to $377.00 and gave the company a market perform rating in a research note on Wednesday, September 13th. On Tuesday, February 7 the stock rating was upgraded by Citigroup to "Buy". The stock of Monsanto Company (NYSE:MON) earned "Mkt Perform" rating by Bernstein on Monday, September 26. The stock of Monsanto Company (NYSE:MON) earned "Overweight" rating by JP Morgan on Wednesday, September 21. OTR Global upgraded the shares of Monday in report on Friday, November 18 to "Mixed" rating. During the same quarter in the previous year, the business posted $5.21 EPS. BIIB's profit will be $1.19 billion for 14.19 P/E if the $5.61 EPS becomes a reality. The biotechnology company reported $5.04 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $4.36 by $0.68.

Investors sentiment increased to 0.95 in 2017 Q2. Its up 0.12, from 0.83 in 2017Q1. It dived, as 81 investors sold BIIB shares while 321 reduced holdings. 78 funds opened positions while 277 raised stakes. 180.66 million shares or 1.01% less from 182.50 million shares in 2017Q1 were reported. The company has a market cap of $67.33 billion, a price-to-earnings ratio of 20.90 and a beta of 0.77. Its up 5.61% from 664,800 shares previously. Steinberg Global Asset Management, Florida-based fund reported 1,538 shares. Woodstock Corp has invested 0.09% in Biogen Inc (NASDAQ:BIIB). Factory Mutual Commerce reported 0.34% stake. Sequoia Advsr Ltd owns 12,544 shares or 0.42% of their United States portfolio. Cullen Frost Bankers Inc reported 16,048 shares or 0.15% of all its holdings. Sva Plumb Wealth Mngmt Limited Company has 6,563 shares. New York-based Klingenstein Fields Ltd Liability Corporation has invested 0.65% in Biogen Inc (NASDAQ:BIIB). Bridgewater Associates Limited Partnership holds 44,981 shares or 0.11% of its portfolio.

Since April 3, 2017, it had 1 insider purchase, and 2 sales for $440,359 activity. 1,402 shares valued at $380,433 were bought by Vounatsos Michel on Monday, May 1. Shares for $542,952 were sold by Sandrock Alfred. Beacon Trust Co. now owns 1,135 shares of the biotechnology company's stock worth $328,000 after acquiring an additional 6 shares during the last quarter.

Tirschwell & Loewy Inc increased International Paper (NYSE:IP) stake by 22,950 shares to 32,550 valued at $1.84 million in 2017Q2. Jpmorgan Chase & Co (AMJ) was raised too. Equities analysts anticipate that Biogen Inc. will post $21.51 earnings per share for the current year. ValuEngine cut shares of Biogen from a buy rating to a hold rating in a research report on Friday, September 1st. Therefore 71% are positive. Biogen has a 52 week low of $244.28 and a 52 week high of $330.00. The stock's average target of $65 is -2.48% below today's ($66.65) share price. Biogen Idec Inc. had 64 analyst reports since July 23, 2015 according to SRatingsIntel.

In other news, EVP Susan H. Alexander sold 7,758 shares of the firm's stock in a transaction that occurred on Wednesday, July 19th. JMP Securities initiated TIER REIT Inc (NYSE:TIER) rating on Friday, January 27. The rating was maintained by Jefferies with "Hold" on Monday, June 12. (NASDAQ:WETF) on Wednesday, June 1 to "Market Perform" rating. The firm has "Buy" rating given on Monday, October 10 by UBS. The stock of Biogen Inc (NASDAQ:BIIB) has "Strong Buy" rating given on Thursday, December 29 by Raymond James. Keefe Bruyette & Woods has "Outperform" rating and $10 target. Citigroup upgraded the shares of BIIB in report on Tuesday, February 7 to "Buy" rating. Hillsdale Inc has invested 0.06% in Biogen Inc (NASDAQ:BIIB).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER